This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Outcomes assessed in the review
The outcomes estimated from the literature were:
test characteristics, prevalence factors, utility values, and discounted quality-adjusted life-years (QALYs) for different scenarios.
Study designs and other criteria for inclusion in the review
It was not stated whether a systematic review of the literature had been undertaken to identify the primary studies. Limited information on the design and characteristics of the primary studies was provided. Survival data came from life tables. Some utility data were estimated from a national sample of HIV-infected adults.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Twelve primary studies provided the clinical data.
Methods of combining primary studies
Most of the primary estimates were not combined since each study provided a series of estimates.
Investigation of differences between primary studies
Not reported.
Results of the review
The sensitivity of the p24 antigen EIA was 0.887 (range: 0.770 -0.957) and the specificity was 0.9996 (range: 0.9950 -0.9999).
The sensitivity of the HIV-1 RNA test was 1 and the specificity was 0.980 (range: 0.950 -0.999).
The sensitivity of the third-generation HIV-1 EIA was 0.790 (range: 0.600 -0.920) and the specificity was 0.970 (range: 0.930 -0.990).
the prevalence in the screened population was 0.66% (range: 0.53 -0.92), the rate of patients who changed behaviour to avoid infecting a sexual partner was 50% (range: 0 -96), the rate of patients that were sexually active was 50% (range: 0 -30), and the rate of infectivity (probability of sexual transmission during PHI period) was 15% (range: 0 -30).
The utility values were 0.937 (range: 0.926 -0.949) for asymptomatic HIV infection and 0.682 (range: 0.400 -0.800) for anxiety while waiting for confirmatory test results for patients with a positive screen.
The discounted QALYs were: 24 for no primary HIV infection;
23.9735 (range: 23.950 -23.983) for positive screening result but no primary HIV infection; 11.9 (range: 11.832 -11.952) for primary HIV infection diagnosed at screening with follow-up care and antiretroviral treatment started at a CD4 cell count of 350 per microL; and 11 for primary HIV infection not diagnosed at screening, or lost to care with antiretroviral treatment started when HIV diagnosed.
Measure of benefits used in the economic analysis
The summary benefit measures used were the QALYs and cases identified. These were estimated using a modelling approach. QALYs associated with different pathways were calculated directly from the literature. The total QALYs associated with the different screening strategies were calculated by multiplying the number of individuals following a certain pathway by the discounted QALYs associated with that pathway. The primary HIV infection cases lost to care (31% of those diagnosed), the false-positive diagnoses, the false-negative diagnoses, and the cases avoided per behaviour change, were also reported as model outputs. An annual discount rate of 3% was applied.
Direct costs
The author stated that a societal perspective was adopted in the analysis of the costs, but transportation costs were not included. The health services considered were the HIV-testing programme, laboratory tests, visits, and the lifetime medical costs for those diagnosed or not diagnosed with primary HIV infection. The cost of the testing programme included HIV counsellors and intake nurses, who arranged for telephone follow-up, visits to homeless shelters and travel vouchers to bring positive patients into care. The unit costs were presented separately from the quantities of resources used for only some items, while lifetime medical costs were presented as macro-categories. The cost of the HIV-testing programme was obtained from a state-funded programme in Massachusetts that offered HIV counselling, testing and referral to more than 3,000 patients entering one of four hospital-associated urgent care centres. The costs of the laboratory tests came from the Medicare fee schedule. Visit costs were estimated from a national survey of physician's office charges. Lifetime medical costs were based on a published simulation model. The source of the resource use data was unclear, but the data seem to have been mainly derived from authors' assumptions and published studies. Discounting was relevant since the costs were incurred over a long timeframe, and an annual rate of 3% was applied.
The price year was 2002, and cost estimates of different fiscal years were inflated to 2002 using the Consumer Price Index.
Statistical analysis of costs
The costs were treated deterministically.
